Company / Revenue
Apellis Pharmaceuticals, Inc. Revenue History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$1.0B
FY2025
5-year range
$66.6M / $1.0B
FY2021-FY2025
Trend
+28.5%
vs FY2024
Sector context
#41 of 155
Health Care
What the data says
At $1.0B, Apellis Pharmaceuticals, Inc.'s revenue ranks #41 of 155 in the Health Care sector. Revenue has increased for 4 consecutive years, from $67M in FY2021 to $1.0B in FY2025.
Based on SEC 10-K filings.
$1.0B in FY2025 with a 5-year CAGR of +32.0%.
Improved from $397M to $1.0B over the past 2 years.
Health Care sector context is included.
Revenue over time
Growth rates
- 3-Year CAGR
- +137.0%
- 5-Year CAGR
- +32.0%
- 10-Year CAGR
- -
Sector benchmark
#41 of 155 in Health CareTop 26% of 155This company $1.0B Sector average $4.5B
▼
-77.5% below sector average
Key checks
Key Insights
- Apellis Pharmaceuticals, Inc.'s revenue has grown for 4 consecutive years.
- 5-year CAGR of +32.0%, indicating consistent growth.
- In FY2025, revenue increased 28.5% year-over-year.
- Ranks #41 out of 155 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -25.3%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.0B | +28.5% |
| FY2024 | $781.4M | +97.0% |
| FY2023 | $396.6M | +425.8% |
| FY2022 | $75.4M | +13.3% |
| FY2021 | $66.6M | -73.4% |
| FY2020 | $250.6M | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026